154 related articles for article (PubMed ID: 15726358)
1. Role of tumor-derived transforming growth factor-beta1 (TGF-beta1) in site-dependent tumorigenicity of murine ascitic lymphosarcoma.
Thakur VS; Shankar B; Chatterjee S; Premachandran S; Sainis KB
Cancer Immunol Immunother; 2005 Sep; 54(9):837-47. PubMed ID: 15726358
[TBL] [Abstract][Full Text] [Related]
2. Resistance to TGF-beta1-mediated growth inhibition correlates with sustained Smad2 phosphorylation in primary murine splenocytes.
Feldmann K; Sebald W; Knaus P
Eur J Immunol; 2002 May; 32(5):1393-402. PubMed ID: 11981827
[TBL] [Abstract][Full Text] [Related]
3. Soluble type II transforming growth factor-beta receptor inhibits established murine malignant mesothelioma tumor growth by augmenting host antitumor immunity.
Suzuki E; Kapoor V; Cheung HK; Ling LE; DeLong PA; Kaiser LR; Albelda SM
Clin Cancer Res; 2004 Sep; 10(17):5907-18. PubMed ID: 15355924
[TBL] [Abstract][Full Text] [Related]
4. Tumor-host interaction mediates the regression of BK virus-induced vascular tumors in mice: involvement of transforming growth factor-beta1.
Corallini A; Possati L; Trabanelli C; Giraudo E; Rocchetti R; Talevi S; Caputo A; Bussolino F; Barbanti-Brodano G
Carcinogenesis; 2003 Sep; 24(9):1435-44. PubMed ID: 12844479
[TBL] [Abstract][Full Text] [Related]
5. Restoration of transforming growth factor beta signaling pathway in human prostate cancer cells suppresses tumorigenicity via induction of caspase-1-mediated apoptosis.
Guo Y; Kyprianou N
Cancer Res; 1999 Mar; 59(6):1366-71. PubMed ID: 10096572
[TBL] [Abstract][Full Text] [Related]
6. Endogenous expression of transforming growth factor beta1 inhibits growth and tumorigenicity and enhances Fas-mediated apoptosis in a murine high-grade glioma model.
Ashley DM; Kong FM; Bigner DD; Hale LP
Cancer Res; 1998 Jan; 58(2):302-9. PubMed ID: 9443409
[TBL] [Abstract][Full Text] [Related]
7. Characteristics of immunity induced by neuraminidase-treated lymphosarcoma cells in C3H (MTV+) and C3H (MTV-) mice.
Bekesi JG; Roboz JP; Holland JF
Isr J Med Sci; 1976; 12(4-5):288-303. PubMed ID: 181351
[TBL] [Abstract][Full Text] [Related]
8. Immune dysfunction in mice with plasmacytomas. I. Evidence that transforming growth factor-beta contributes to the altered expression of activation receptors on host B lymphocytes.
Berg DJ; Lynch RG
J Immunol; 1991 Apr; 146(8):2865-72. PubMed ID: 1826699
[TBL] [Abstract][Full Text] [Related]
9. Soluble and membrane-bound TGF-β-mediated regulation of intratumoral T cell differentiation and function in B-cell non-Hodgkin lymphoma.
Yang ZZ; Grote DM; Ziesmer SC; Xiu B; Yates NR; Secreto FJ; Hodge LS; Witzig TE; Novak AJ; Ansell SM
PLoS One; 2013; 8(3):e59456. PubMed ID: 23555036
[TBL] [Abstract][Full Text] [Related]
10. Rapamycin can restore the negative regulatory function of transforming growth factor beta 1 in high grade lymphomas.
Sebestyén A; Márk Á; Hajdu M; Nagy N; Molnár A; Végső G; Barna G; Kopper L
Cytokine; 2015 Jun; 73(2):219-24. PubMed ID: 25794661
[TBL] [Abstract][Full Text] [Related]
11. Particular types of tumor cells have the capacity to convert transforming growth factor beta from a latent to an active form.
Takiuchi H; Tada T; Li XF; Ogata M; Ikeda T; Fujimoto S; Fujiwara H; Hamaoka T
Cancer Res; 1992 Oct; 52(20):5641-6. PubMed ID: 1327512
[TBL] [Abstract][Full Text] [Related]
12. Suppression of latent transforming growth factor-β (TGF-β)-binding protein 1 (LTBP1) inhibits natural killer/ T cell lymphoma progression by inactivating the TGF-β/Smad and p38
Lin R; Li X; Wu S; Qian S; Hou H; Dong M; Zhang X; Zhang M
Exp Cell Res; 2021 Oct; 407(1):112790. PubMed ID: 34418460
[TBL] [Abstract][Full Text] [Related]
13. The inhibitory effects of transforming growth factor-beta-1 (TGF-beta1) in autoimmune diseases.
Prud'homme GJ; Piccirillo CA
J Autoimmun; 2000 Feb; 14(1):23-42. PubMed ID: 10648114
[TBL] [Abstract][Full Text] [Related]
14. Transforming growth factor-beta1 released from the spleen exerts a growth inhibitory effect on liver regeneration in rats.
Ueda S; Yamanoi A; Hishikawa Y; Dhar DK; Tachibana M; Nagasue N
Lab Invest; 2003 Nov; 83(11):1595-603. PubMed ID: 14615413
[TBL] [Abstract][Full Text] [Related]
15. Increased transforming growth factor beta expression inhibits cell proliferation in vitro, yet increases tumorigenicity and tumor growth of Meth A sarcoma cells.
Chang HL; Gillett N; Figari I; Lopez AR; Palladino MA; Derynck R
Cancer Res; 1993 Sep; 53(18):4391-8. PubMed ID: 8364935
[TBL] [Abstract][Full Text] [Related]
16. Transforming growth factor beta from multiple myeloma cells inhibits proliferation and IL-2 responsiveness in T lymphocytes.
Cook G; Campbell JD; Carr CE; Boyd KS; Franklin IM
J Leukoc Biol; 1999 Dec; 66(6):981-8. PubMed ID: 10614781
[TBL] [Abstract][Full Text] [Related]
17. Transforming growth factor-beta1 down-regulates expression of chemokine stromal cell-derived factor-1: functional consequences in cell migration and adhesion.
Wright N; de Lera TL; García-Moruja C; Lillo R; García-Sánchez F; Caruz A; Teixidó J
Blood; 2003 Sep; 102(6):1978-84. PubMed ID: 12775566
[TBL] [Abstract][Full Text] [Related]
18. IL-2 gene and antisense TGF-beta1 strategies counteract HSV-2 transformed tumor progression.
Kettering JD; Mohamedali AM; Green LM; Gridley DS
Technol Cancer Res Treat; 2003 Jun; 2(3):211-21. PubMed ID: 12779352
[TBL] [Abstract][Full Text] [Related]
19. Concentrations of cyclosporin A and FK506 that inhibit IL-2 induction in human T cells do not affect TGF-beta1 biosynthesis, whereas higher doses of cyclosporin A trigger apoptosis and release of preformed TGF-beta1.
Minguillón J; Morancho B; Kim SJ; López-Botet M; Aramburu J
J Leukoc Biol; 2005 May; 77(5):748-58. PubMed ID: 15716327
[TBL] [Abstract][Full Text] [Related]
20. Tumor-induced regulation of suppressor macrophage nitric oxide and TNF-alpha production. Role of tumor-derived IL-10, TGF-beta, and prostaglandin E2.
Alleva DG; Burger CJ; Elgert KD
J Immunol; 1994 Aug; 153(4):1674-86. PubMed ID: 8046239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
